In accordance with the decision taken at the annual general meeting on May 27, 2021, the three largest shareholders as of September 30, 2021 have been contacted by the chairman of the board and been offered to appoint a member each to the nomination committee of Nanologica AB.
The three largest shareholders as of September 30, 2021 have each appointed one representative so that the nomination committee for the annual general meeting 2022 consists of the following members:
Carl-Johan Spak (Flerie Invest AB)
Lennart Francke (Swedbank Robur Medica)
Joakim Persson (Vega Bianca AB)
The nomination committee together represents 48.3 percent of the total number of votes in Nanologica AB as of September 30, 2021.
The nomination committee's task is to present proposals for resolutions for the annual general meeting 2022 regarding election of chairman of the meeting, number of board members to be elected by the meeting, election of the board of directors and chairman of the board, fees and other remuneration to the board of directors and its committees, election of auditors (if applicable) and remuneration to auditors, and proposal for the principles that will apply to the composition and work of the nomination committee for the next annual general meeting.
Nanologica's annual general meeting 2022 will be held in Stockholm June 2, 2022. Shareholders wishing to submit proposals to the nomination committee can contact the committee by e-mail to firstname.lastname@example.org no later than January 31, 2022.
For further information, please contact:
Gisela Sitbon, chairman of the board
Ph: +46 70 282 55 58 or e-mail: email@example.com
About Nanologica AB (publ)
2021-10-29 Nanologica Announces the Nomination Committee for the 2022 Annual General Meeting
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company's share (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.